Cardinal Health completes Biotech acquisition

August 12, 2009

Cardinal Health has agreed to acquire the assets of privately held Biotech, an operator of Positron Emission Tomography (PET) cyclotrons and nuclear pharmacies in the southwestern United States.

Cardinal Health  has agreed to acquire the assets of privately held Biotech, an operator of Positron Emission Tomography (PET) cyclotrons and nuclear pharmacies in the southwestern United States.

With the addition of Biotech’s four nuclear pharmacies, Cardinal Health will expand its existing U.S. PET business. The facilities are located across Arizona, Nevada, New Mexico, and Texas. In addition to the manufacture and distribution of fluorodeoxyglucose (FDG)-based PET agents, Cardinal Health recently opened its network to support clinical trials of new and novel PET agents to advance the future of molecular imaging.

As well as helping manufacturers expand the pipeline of new agents that will aid in the diagnosis and treatment of disease, the company also works with pharmaceutical companies and physicians interested in using PET products to determine the efficacy of therapeutic medications, the company said in a statement.

“The Biotech acquisition helps demonstrate Cardinal Health’s commitment to advancing the future of molecular imaging, accelerates the build-out of our PET business, and augments our leading network of nuclear pharmacies,” said John Rademacher, president and general manager of Nuclear and Specialty Pharmacy Services for Cardinal Health. “In addition to their facilities across the Southwestern U.S., Biotech’s highly skilled employees and their intellectual property will be immediately applicable to support our expanding role in supporting new drug development.”

In addition to operating the broadest radiopharmacy network in the United States, Cardinal Health is also the largest employer of nuclear pharmacists in the world.